G1T48: Experimental Treatment for Estrogen Receptor-Positive, HER2-Negative (ER+, HER2-) Breast Cancer

Scientific rationale and therapeutic potential

G1T48 is oral selective estrogen receptor degrader (SERD) designed to inhibit estrogen receptor driven tumor growth as a single agent and in combination with other anti-cancer therapies, including CDK 4/6 inhibitors such as G1T38. G1T48 has the potential to be a first-in-class oral SERD.

Preclinical results (see: Publications)

- published preclinical data demonstrating G1T48 to be more potent than Faslodex® and to have superior anti-tumor efficacy versus other SERDs in development;
- this is the first clinical trial of G1T48 in ER+, HER2- breast cancer.

G1 is recruiting patients for a Phase 1/2a trial in ER+, HER2- breast cancer

G1T48-01 Trial

- estrogen receptor-positive (ER+), HER2-negative metastatic breast cancer
- multi-center, open-label
- G1T48 monotherapy
- approximately 95 patients
- ClinicalTrials.gov identifier: NCT03455270

79 T.W. Alexander Drive | 4501 Research Commons, Suite 100 | Research Triangle Park, NC 27709
www.g1therapeutics.com | contact: clinicalinfo@g1therapeutics.com